FMG denied to appear in screening test for being underage during MBBS admission abroad: Madras HC directs NMC to allow medico to appear in screening test

Powered by WPeMatico
Powered by WPeMatico
Thiruvananthapuram: Kerala’s Health Minister, Veena George, has announced plans to ramp up efforts to prevent the spread of the Nipah virus in the state, particularly during the months from May to September when the virus is most active.
Minister George emphasized the importance of extreme caution and outlined several key preventive measures.
According to an ANI news report, She urged the public not to destroy bat habitats, as disturbing these could increase the risk of virus transmission. Additionally, she advised against consuming fruits that have been bitten by birds and drinking honey from banana peels, both of which could be contaminated by bats.
Veena George also highlighted the necessity of proper hygiene, recommending that hands should be thoroughly washed with soap and water if they come into contact with bats, their excrement, or objects they have bitten.
“We must all be vigilant and proactive in our efforts to prevent the spread of Nipah. By following these guidelines, we can protect ourselves and our loved ones,” said Minister George.
She stressed the importance of educating children about these precautions to ensure community-wide awareness and safety.
Nipah Virus, transmitted from animals to humans, can lead to severe illness and fatalities.
On May 19, 2018, a Nipah virus disease (NiV) outbreak was reported in Kozhikode district of Kerala. This was the first NiV outbreak in South India.
According to the World Health Organization (WHO), there were 17 deaths and 18 confirmed cases as of June 1, 2018. The two affected districts were Kozhikode and Mallapuram, news agency ANI reported.
The Nipah outbreak reported in Kozhikode and Malappuram districts of Kerala in May 2018 was the third Nipah virus outbreak in India, the earlier being in 2001 and 2007, both in West Bengal.
Despite the challenges posed by the outbreak, Kerala’s robust health system played a vital role in containing its spread. The state’s proactive measures and emphasis on public health education contributed to its ability to manage the situation effectively.
Powered by WPeMatico
Here are the top health stories for the day:
Madras HC grants relief to underage FMG, directs NMC to allow screening test participation
Powered by WPeMatico
Tata Capital Healthcare Fund II, an arm of Tata Capital has injected USD 20 million in Orbicular Pharmaceutical Technologies for an undisclosed stake.
According to the statement, Tata Capital Healthcare Fund II has made the investment in the Hyderabad-based specialty pharmaceutical company and the proceeds will be utilised for accelerating product development,
As per PTI, the statement said the USD 60 billion specialty generics industry is expanding rapidly driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications, and Orbicular has a pipeline of niche products in the specialty generics space catering to the demand.
“This investment reinforces our fund’s core philosophy of identifying the big shifts in the industry and being a “capital plus” partner to our companies,” Visalakshi Chandramouli, Managing Partner, Tata Capital Healthcare Fund said.
“Having positioned Orbicular as a differentiated specialty pharmaceutical company in the complex generics space, the investment will further strengthen our global partnerships,” the company’s Managing Director M S Mohan.
The Tata Capital Healthcare Fund (‘TCHF’) is a growth oriented private equity fund focused on the healthcare and lifesciences sector in India. The fund is sponsored by Tata Capital Limited, a subsidiary of Tata Sons Limited. TCHF has raised ~ US$ 200 million across two funds – TCHF I (2012) and TCHF II (2022). Across both the funds, TCHF has invested in 16 companies, and has successfully exited 6 companies thus far.
Read also: Tata Capital health division pours USD 10 million investment into Apex Kidney Care
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
New Delhi: Sun Pharmaceutical Industries, a leading pharmaceutical company, anticipates achieving a robust single-digit top line increase in revenue for the current fiscal, as stated by Managing Director Dilip Shanghvi.
In FY24, the Mumbai-headquartered company disclosed a consolidated total revenue from operations at Rs 48,497 crore, compared to Rs 43,886 crore in FY23.
“We expect high single-digit consolidated top line growth for FY25. All our businesses are positioned for growth,” Shanghvi said in an analyst call.
Read also: Sun Pharma new plant inaugurated in Bangladesh
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
Powered by WPeMatico